Micromet: Low-dose MT103/MEDI-538 shows clinical activity in lymphoma patients

By Elaine Rigoli

Tampa, Fla., June 16 - Micromet released the first results from the ongoing phase 1 study of MT103-104 that indicated that low doses of continuously infused MT103/MEDI-538 as a single-agent therapy have clinical activity in heavily pre-treated non-Hodgkin's lymphoma patients.

MT103/MEDI-538 is a murine recombinant single-chain antibody derivative that combines in one molecule the binding specificity for both the pan-B cell antigen CD19 and the epsilon chain of the T cell receptor/CD3 complex1-4, the company said.

Recent studies have shown that MT103-activated T cells are capable of serial tumor cell killing, translating into activity at very low effector-target cell ratios.

Micromet is a research pharmaceutical company located in Carlsbad, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.